2014-01-22 22:15:43 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit. www.fastmr.com/prod/764036_pharmapoint_atopic_dermatitis_us_drug ..
By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.
Full Report Details at
However, these classes represent the crowded, saturated, generic portion of the US atopic dermatitis market, with little room for innovative products. That said, the reliance on these agents will lead to an overall steady growth over the 10-year forecast period, with respective CAGRs of 1.2% and 0.5% for corticosteroids and moisturizers/emollients during this timeframe.
* Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in the US from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting the US Atopic Dermatitis market.
Reasons to Get this Report
* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in the US
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
4 Disease Management
4.2 Treatment Overview
4.3.2 Clinical Practice
5 Competitive Assessment
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Protopic (tacrolimus)
5.3.3 Cyclosporine (numerous generic names)
5.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis
5.4 Product Profiles - Off-Label Therapies
5.4.1 Actimmune (interferon gamma-1b)
6 Opportunity and Unmet Need
6.2 Unmet Needs
6.2.1 A Systemic Drug for Severe Recalcitrant Patients
6.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach
6.2.3 A Drug that Effectively Controls Patients' Pruritus
6.2.4 Further Research into the Pathophysiology of Atopic Dermatitis
6.2.5 A Drug that Induces Disease Remission
6.2.6 Improved Quality of Life for Both Patients and their Carers
6.3 Unmet Needs Gap Analysis
6.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients
6.4.2 Predictive Tests for Patient Stratification
6.4.3 More Therapeutic Options that Address Patients' Pruritus
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
7.2.1 Dupilumab (SAR231893/ REGN668)
7.2.3 Phase II Pipeline Products
8 Market Outlook
8.1 Global Drivers and Barriers
8.1.1 Driver: Anticipated launch of the first biologic for the treatment of moderate to severe disease
8.1.2 Driver: The underserved severe refractory patient segment presents an untapped market opportunity
8.1.3 Driver: A drug that is able to target two or more atopic diseases would gain a foothold in these markets
8.1.4 Driver: Atopic dermatitis presents an attractive patient population for drug developers
8.1.5 Driver: Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents
8.1.6 Barrier: First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market
8.1.7 Barrier: The largest atopic dermatitis patient segment - mild disease - can be well-controlled on most forms of topical therapy
8.1.8 Barrier: Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products
8.1.9 Barrier: The complexity of the multiple etiologies that lead to atopic dermatitis means that treatment outcomes with existing drugs are not universal across all patient groups
8.1.10 Barrier: A significant proportion of patients experience disease remission in their early adolescent years and this may occur without drug therapy
8.2.2 Key Events
8.2.3 Drivers and Barriers
9.4 Forecasting Methodology
9.4.1 Diagnosed Atopic Dermatitis Patients
9.4.2 Percent Drug-treated Patients
Full Table of Contents is available at:
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.